Report Cover

Global COVID-19 Inactivated Vaccine Market 2021 by Company, Regions, Type and Application, Forecast to 2026


The COVID-19 Inactivated Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global COVID-19 Inactivated Vaccine size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global COVID-19 Inactivated Vaccine market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
COVID-19 Inactivated Vaccine market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    In Clinical Trials
    Out-of-Clinical Trials

Market segment by Application, can be divided into
    Hospital
    Clinic
    Other

Market segment by players, this report covers
    Inovio Pharmaceuticals
    Takis Biotech (Evvivax)
    Zydus Cadila
    Codagenix, Inc.
    GeoVax, Inc.
    Bravovax
    Janssen Pharmaceutical Companies
    Altimmune
    Vaxart
    CanSino Biologics
    ExpreS2ion Biotechnologies ApS
    Clover Biopharmaceuticals
    GSK
    Vaxil Bio Ltd.
    Generex
    Novavax, Inc.
    Sanofi Pasteur
    Baylor
    iBio, Inc.
    Moderna, Inc.
    Curevac
    ImmunoPrecise

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
    1.1 Product Overview and Scope of COVID-19 Inactivated Vaccine
    1.2 Classification of COVID-19 Inactivated Vaccine by Type
        1.2.1 Overview: Global COVID-19 Inactivated Vaccine Market Size by Type: 2020 Versus 2021 Versus 2026
        1.2.2 Global COVID-19 Inactivated Vaccine Revenue Market Share by Type in 2020
        1.2.3 In Clinical Trials
        1.2.4 Out-of-Clinical Trials
    1.3 Global COVID-19 Inactivated Vaccine Market by Application
        1.3.1 Overview: Global COVID-19 Inactivated Vaccine Market Size by Application: 2020 Versus 2021 Versus 2026
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Other
    1.4 Global COVID-19 Inactivated Vaccine Market Size & Forecast
    1.5 Global COVID-19 Inactivated Vaccine Market Size and Forecast by Region
        1.5.1 Global COVID-19 Inactivated Vaccine Market Size by Region: 2016 VS 2021 VS 2026
        1.5.2 Global COVID-19 Inactivated Vaccine Market Size by Region, (2016-2021)
        1.5.3 North America COVID-19 Inactivated Vaccine Market Size and Prospect (2016-2026)
        1.5.4 Europe COVID-19 Inactivated Vaccine Market Size and Prospect (2016-2026)
        1.5.5 Asia-Pacific COVID-19 Inactivated Vaccine Market Size and Prospect (2016-2026)
        1.5.6 South America COVID-19 Inactivated Vaccine Market Size and Prospect (2016-2026)
        1.5.7 Middle East and Africa COVID-19 Inactivated Vaccine Market Size and Prospect (2016-2026)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 COVID-19 Inactivated Vaccine Market Drivers
        1.6.2 COVID-19 Inactivated Vaccine Market Restraints
        1.6.3 COVID-19 Inactivated Vaccine Trends Analysis
2 Company Profiles
    2.1 Inovio Pharmaceuticals
        2.1.1 Inovio Pharmaceuticals Details
        2.1.2 Inovio Pharmaceuticals Major Business
        2.1.3 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Product and Solutions
        2.1.4 Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.1.5 Inovio Pharmaceuticals Recent Developments and Future Plans
    2.2 Takis Biotech (Evvivax)
        2.2.1 Takis Biotech (Evvivax) Details
        2.2.2 Takis Biotech (Evvivax) Major Business
        2.2.3 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Product and Solutions
        2.2.4 Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.2.5 Takis Biotech (Evvivax) Recent Developments and Future Plans
    2.3 Zydus Cadila
        2.3.1 Zydus Cadila Details
        2.3.2 Zydus Cadila Major Business
        2.3.3 Zydus Cadila COVID-19 Inactivated Vaccine Product and Solutions
        2.3.4 Zydus Cadila COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.3.5 Zydus Cadila Recent Developments and Future Plans
    2.4 Codagenix, Inc.
        2.4.1 Codagenix, Inc. Details
        2.4.2 Codagenix, Inc. Major Business
        2.4.3 Codagenix, Inc. COVID-19 Inactivated Vaccine Product and Solutions
        2.4.4 Codagenix, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.4.5 Codagenix, Inc. Recent Developments and Future Plans
    2.5 GeoVax, Inc.
        2.5.1 GeoVax, Inc. Details
        2.5.2 GeoVax, Inc. Major Business
        2.5.3 GeoVax, Inc. COVID-19 Inactivated Vaccine Product and Solutions
        2.5.4 GeoVax, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.5.5 GeoVax, Inc. Recent Developments and Future Plans
    2.6 Bravovax
        2.6.1 Bravovax Details
        2.6.2 Bravovax Major Business
        2.6.3 Bravovax COVID-19 Inactivated Vaccine Product and Solutions
        2.6.4 Bravovax COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.6.5 Bravovax Recent Developments and Future Plans
    2.7 Janssen Pharmaceutical Companies
        2.7.1 Janssen Pharmaceutical Companies Details
        2.7.2 Janssen Pharmaceutical Companies Major Business
        2.7.3 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Product and Solutions
        2.7.4 Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.7.5 Janssen Pharmaceutical Companies Recent Developments and Future Plans
    2.8 Altimmune
        2.8.1 Altimmune Details
        2.8.2 Altimmune Major Business
        2.8.3 Altimmune COVID-19 Inactivated Vaccine Product and Solutions
        2.8.4 Altimmune COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.8.5 Altimmune Recent Developments and Future Plans
    2.9 Vaxart
        2.9.1 Vaxart Details
        2.9.2 Vaxart Major Business
        2.9.3 Vaxart COVID-19 Inactivated Vaccine Product and Solutions
        2.9.4 Vaxart COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.9.5 Vaxart Recent Developments and Future Plans
    2.10 CanSino Biologics 
        2.10.1 CanSino Biologics Details
        2.10.2 CanSino Biologics Major Business
        2.10.3 CanSino Biologics COVID-19 Inactivated Vaccine Product and Solutions
        2.10.4 CanSino Biologics COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.10.5 CanSino Biologics Recent Developments and Future Plans
    2.11 ExpreS2ion Biotechnologies ApS
        2.11.1 ExpreS2ion Biotechnologies ApS Details
        2.11.2 ExpreS2ion Biotechnologies ApS Major Business
        2.11.3 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Product and Solutions
        2.11.4 ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.11.5 ExpreS2ion Biotechnologies ApS Recent Developments and Future Plans
    2.12 Clover Biopharmaceuticals
        2.12.1 Clover Biopharmaceuticals Details
        2.12.2 Clover Biopharmaceuticals Major Business
        2.12.3 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Product and Solutions
        2.12.4 Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.12.5 Clover Biopharmaceuticals Recent Developments and Future Plans
    2.13 GSK
        2.13.1 GSK Details
        2.13.2 GSK Major Business
        2.13.3 GSK COVID-19 Inactivated Vaccine Product and Solutions
        2.13.4 GSK COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.13.5 GSK Recent Developments and Future Plans
    2.14 Vaxil Bio Ltd.
        2.14.1 Vaxil Bio Ltd. Details
        2.14.2 Vaxil Bio Ltd. Major Business
        2.14.3 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Product and Solutions
        2.14.4 Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.14.5 Vaxil Bio Ltd. Recent Developments and Future Plans
    2.15 Generex
        2.15.1 Generex Details
        2.15.2 Generex Major Business
        2.15.3 Generex COVID-19 Inactivated Vaccine Product and Solutions
        2.15.4 Generex COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.15.5 Generex Recent Developments and Future Plans
    2.16 Novavax, Inc.
        2.16.1 Novavax, Inc. Details
        2.16.2 Novavax, Inc. Major Business
        2.16.3 Novavax, Inc. COVID-19 Inactivated Vaccine Product and Solutions
        2.16.4 Novavax, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.16.5 Novavax, Inc. Recent Developments and Future Plans
    2.17 Sanofi Pasteur
        2.17.1 Sanofi Pasteur Details
        2.17.2 Sanofi Pasteur Major Business
        2.17.3 Sanofi Pasteur COVID-19 Inactivated Vaccine Product and Solutions
        2.17.4 Sanofi Pasteur COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.17.5 Sanofi Pasteur Recent Developments and Future Plans
    2.18 Baylor
        2.18.1 Baylor Details
        2.18.2 Baylor Major Business
        2.18.3 Baylor COVID-19 Inactivated Vaccine Product and Solutions
        2.18.4 Baylor COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.18.5 Baylor Recent Developments and Future Plans
    2.19 iBio, Inc.
        2.19.1 iBio, Inc. Details
        2.19.2 iBio, Inc. Major Business
        2.19.3 iBio, Inc. COVID-19 Inactivated Vaccine Product and Solutions
        2.19.4 iBio, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.19.5 iBio, Inc. Recent Developments and Future Plans
    2.20 Moderna, Inc.
        2.20.1 Moderna, Inc. Details
        2.20.2 Moderna, Inc. Major Business
        2.20.3 Moderna, Inc. COVID-19 Inactivated Vaccine Product and Solutions
        2.20.4 Moderna, Inc. COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.20.5 Moderna, Inc. Recent Developments and Future Plans
    2.21 Curevac
        2.21.1 Curevac Details
        2.21.2 Curevac Major Business
        2.21.3 Curevac COVID-19 Inactivated Vaccine Product and Solutions
        2.21.4 Curevac COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.21.5 Curevac Recent Developments and Future Plans
    2.22 ImmunoPrecise
        2.22.1 ImmunoPrecise Details
        2.22.2 ImmunoPrecise Major Business
        2.22.3 ImmunoPrecise COVID-19 Inactivated Vaccine Product and Solutions
        2.22.4 ImmunoPrecise COVID-19 Inactivated Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.22.5 ImmunoPrecise Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global COVID-19 Inactivated Vaccine Revenue and Share by Players (2019-2021)
    3.2 Market Concentration Rate
        3.2.1 Top 3 COVID-19 Inactivated Vaccine Players Market Share
        3.2.2 Top 10 COVID-19 Inactivated Vaccine Players Market Share
        3.2.3 Market Competition Trend
    3.3 COVID-19 Inactivated Vaccine Players Head Office, Products and Services Provided
    3.4 Mergers & Acquisitions
    3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Global COVID-19 Inactivated Vaccine Revenue and Market Share by Type (2016-2021)
    4.2 Global COVID-19 Inactivated Vaccine Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
    5.1 Global COVID-19 Inactivated Vaccine Revenue Market Share by Application (2016-2021)
    5.2 COVID-19 Inactivated Vaccine Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
    6.1 North America COVID-19 Inactivated Vaccine Revenue by Type (2016-2026)
    6.2 North America COVID-19 Inactivated Vaccine Revenue by Application (2016-2026)
    6.3 North America COVID-19 Inactivated Vaccine Market Size by Country
        6.3.1 North America COVID-19 Inactivated Vaccine Revenue by Country (2016-2026)
        6.3.2 United States COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        6.3.3 Canada COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        6.3.4 Mexico COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
    7.1 Europe COVID-19 Inactivated Vaccine Revenue by Type (2016-2026)
    7.2 Europe COVID-19 Inactivated Vaccine Revenue by Application (2016-2026)
    7.3 Europe COVID-19 Inactivated Vaccine Market Size by Country
        7.3.1 Europe COVID-19 Inactivated Vaccine Revenue by Country (2016-2026)
        7.3.2 Germany COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        7.3.3 France COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        7.3.4 United Kingdom COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        7.3.5 Russia COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        7.3.6 Italy COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Type (2016-2026)
    8.2 Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Application (2016-2026)
    8.3 Asia-Pacific COVID-19 Inactivated Vaccine Market Size by Region
        8.3.1 Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Region (2016-2026)
        8.3.2 China COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        8.3.3 Japan COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        8.3.4 South Korea COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        8.3.5 India COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        8.3.6 Southeast Asia COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        8.3.7 Australia COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
    9.1 South America COVID-19 Inactivated Vaccine Revenue by Type (2016-2026)
    9.2 South America COVID-19 Inactivated Vaccine Revenue by Application (2016-2026)
    9.3 South America COVID-19 Inactivated Vaccine Market Size by Country
        9.3.1 South America COVID-19 Inactivated Vaccine Revenue by Country (2016-2026)
        9.3.2 Brazil COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        9.3.3 Argentina COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Type (2016-2026)
    10.2 Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Application (2016-2026)
    10.3 Middle East & Africa COVID-19 Inactivated Vaccine Market Size by Country
        10.3.1 Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Country (2016-2026)
        10.3.2 Turkey COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        10.3.3 Saudi Arabia COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
        10.3.4 UAE COVID-19 Inactivated Vaccine Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

List of Tables Table 1. Global COVID-19 Inactivated Vaccine Revenue by Type, (USD Million), 2020 VS 2021 VS 2026 Table 2. Global COVID-19 Inactivated Vaccine Revenue by Application, (USD Million), 2020 VS 2021 VS 2026 Table 3. Global Market COVID-19 Inactivated Vaccine Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026) Table 4. Global COVID-19 Inactivated Vaccine Revenue (USD Million) by Region (2016-2021) Table 5. Global COVID-19 Inactivated Vaccine Revenue Market Share by Region (2021-2026) Table 6. Inovio Pharmaceuticals Corporate Information, Head Office, and Major Competitors Table 7. Inovio Pharmaceuticals Major Business Table 8. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Product and Solutions Table 9. Inovio Pharmaceuticals COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 10. Takis Biotech (Evvivax) Corporate Information, Head Office, and Major Competitors Table 11. Takis Biotech (Evvivax) Major Business Table 12. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Product and Solutions Table 13. Takis Biotech (Evvivax) COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 14. Zydus Cadila Corporate Information, Head Office, and Major Competitors Table 15. Zydus Cadila Major Business Table 16. Zydus Cadila COVID-19 Inactivated Vaccine Product and Solutions Table 17. Zydus Cadila COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 18. Codagenix, Inc. Corporate Information, Head Office, and Major Competitors Table 19. Codagenix, Inc. Major Business Table 20. Codagenix, Inc. COVID-19 Inactivated Vaccine Product and Solutions Table 21. Codagenix, Inc. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 22. GeoVax, Inc. Corporate Information, Head Office, and Major Competitors Table 23. GeoVax, Inc. Major Business Table 24. GeoVax, Inc. COVID-19 Inactivated Vaccine Product and Solutions Table 25. GeoVax, Inc. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 26. Bravovax Corporate Information, Head Office, and Major Competitors Table 27. Bravovax Major Business Table 28. Bravovax COVID-19 Inactivated Vaccine Product and Solutions Table 29. Bravovax COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 30. Janssen Pharmaceutical Companies Corporate Information, Head Office, and Major Competitors Table 31. Janssen Pharmaceutical Companies Major Business Table 32. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Product and Solutions Table 33. Janssen Pharmaceutical Companies COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 34. Altimmune Corporate Information, Head Office, and Major Competitors Table 35. Altimmune Major Business Table 36. Altimmune COVID-19 Inactivated Vaccine Product and Solutions Table 37. Altimmune COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 38. Vaxart Corporate Information, Head Office, and Major Competitors Table 39. Vaxart Major Business Table 40. Vaxart COVID-19 Inactivated Vaccine Product and Solutions Table 41. Vaxart COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 42. CanSino Biologics Corporate Information, Head Office, and Major Competitors Table 43. CanSino Biologics Major Business Table 44. CanSino Biologics COVID-19 Inactivated Vaccine Product and Solutions Table 45. CanSino Biologics COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 46. ExpreS2ion Biotechnologies ApS Corporate Information, Head Office, and Major Competitors Table 47. ExpreS2ion Biotechnologies ApS Major Business Table 48. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Product and Solutions Table 49. ExpreS2ion Biotechnologies ApS COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 50. Clover Biopharmaceuticals Corporate Information, Head Office, and Major Competitors Table 51. Clover Biopharmaceuticals Major Business Table 52. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Product and Solutions Table 53. Clover Biopharmaceuticals COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 54. GSK Corporate Information, Head Office, and Major Competitors Table 55. GSK Major Business Table 56. GSK COVID-19 Inactivated Vaccine Product and Solutions Table 57. GSK COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 58. Vaxil Bio Ltd. Corporate Information, Head Office, and Major Competitors Table 59. Vaxil Bio Ltd. Major Business Table 60. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Product and Solutions Table 61. Vaxil Bio Ltd. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 62. Generex Corporate Information, Head Office, and Major Competitors Table 63. Generex Major Business Table 64. Generex COVID-19 Inactivated Vaccine Product and Solutions Table 65. Generex COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 66. Novavax, Inc. Corporate Information, Head Office, and Major Competitors Table 67. Novavax, Inc. Major Business Table 68. Novavax, Inc. COVID-19 Inactivated Vaccine Product and Solutions Table 69. Novavax, Inc. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 70. Sanofi Pasteur Corporate Information, Head Office, and Major Competitors Table 71. Sanofi Pasteur Major Business Table 72. Sanofi Pasteur COVID-19 Inactivated Vaccine Product and Solutions Table 73. Sanofi Pasteur COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 74. Baylor Corporate Information, Head Office, and Major Competitors Table 75. Baylor Major Business Table 76. Baylor COVID-19 Inactivated Vaccine Product and Solutions Table 77. Baylor COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 78. iBio, Inc. Corporate Information, Head Office, and Major Competitors Table 79. iBio, Inc. Major Business Table 80. iBio, Inc. COVID-19 Inactivated Vaccine Product and Solutions Table 81. iBio, Inc. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 82. Moderna, Inc. Corporate Information, Head Office, and Major Competitors Table 83. Moderna, Inc. Major Business Table 84. Moderna, Inc. COVID-19 Inactivated Vaccine Product and Solutions Table 85. Moderna, Inc. COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 86. Curevac Corporate Information, Head Office, and Major Competitors Table 87. Curevac Major Business Table 88. Curevac COVID-19 Inactivated Vaccine Product and Solutions Table 89. Curevac COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 90. ImmunoPrecise Corporate Information, Head Office, and Major Competitors Table 91. ImmunoPrecise Major Business Table 92. ImmunoPrecise COVID-19 Inactivated Vaccine Product and Solutions Table 93. ImmunoPrecise COVID-19 Inactivated Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 94. Global COVID-19 Inactivated Vaccine Revenue (USD Million) by Players (2019-2021) Table 95. Global COVID-19 Inactivated Vaccine Revenue Share by Players (2019-2021) Table 96. Breakdown of COVID-19 Inactivated Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) Table 97. COVID-19 Inactivated Vaccine Players Head Office, Products and Services Provided Table 98. COVID-19 Inactivated Vaccine Mergers & Acquisitions in the Past Five Years Table 99. COVID-19 Inactivated Vaccine New Entrants and Expansion Plans Table 100. Global COVID-19 Inactivated Vaccine Revenue (USD Million) by Type (2016-2021) Table 101. Global COVID-19 Inactivated Vaccine Revenue Share by Type (2016-2021) Table 102. Global COVID-19 Inactivated Vaccine Revenue Forecast by Type (2021-2026) Table 103. Global COVID-19 Inactivated Vaccine Revenue by Application (2016-2021) Table 104. Global COVID-19 Inactivated Vaccine Revenue Forecast by Application (2021-2026) Table 105. North America COVID-19 Inactivated Vaccine Revenue by Type (2016-2021) & (USD Million) Table 106. North America COVID-19 Inactivated Vaccine Revenue by Type (2021-2026) & (USD Million) Table 107. North America COVID-19 Inactivated Vaccine Revenue by Application (2016-2021) & (USD Million) Table 108. North America COVID-19 Inactivated Vaccine Revenue by Application (2021-2026) & (USD Million) Table 109. North America COVID-19 Inactivated Vaccine Revenue by Country (2016-2021) & (USD Million) Table 110. North America COVID-19 Inactivated Vaccine Revenue by Country (2021-2026) & (USD Million) Table 111. Europe COVID-19 Inactivated Vaccine Revenue by Type (2016-2021) & (USD Million) Table 112. Europe COVID-19 Inactivated Vaccine Revenue by Type (2021-2026) & (USD Million) Table 113. Europe COVID-19 Inactivated Vaccine Revenue by Application (2016-2021) & (USD Million) Table 114. Europe COVID-19 Inactivated Vaccine Revenue by Application (2021-2026) & (USD Million) Table 115. Europe COVID-19 Inactivated Vaccine Revenue by Country (2016-2021) & (USD Million) Table 116. Europe COVID-19 Inactivated Vaccine Revenue by Country (2021-2026) & (USD Million) Table 117. Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Type (2016-2021) & (USD Million) Table 118. Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Type (2021-2026) & (USD Million) Table 119. Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Application (2016-2021) & (USD Million) Table 120. Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Application (2021-2026) & (USD Million) Table 121. Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Region (2016-2021) & (USD Million) Table 122. Asia-Pacific COVID-19 Inactivated Vaccine Revenue by Region (2021-2026) & (USD Million) Table 123. South America COVID-19 Inactivated Vaccine Revenue by Type (2016-2021) & (USD Million) Table 124. South America COVID-19 Inactivated Vaccine Revenue by Type (2021-2026) & (USD Million) Table 125. South America COVID-19 Inactivated Vaccine Revenue by Application (2016-2021) & (USD Million) Table 126. South America COVID-19 Inactivated Vaccine Revenue by Application (2021-2026) & (USD Million) Table 127. South America COVID-19 Inactivated Vaccine Revenue by Country (2016-2021) & (USD Million) Table 128. South America COVID-19 Inactivated Vaccine Revenue by Country (2021-2026) & (USD Million) Table 129. Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Type (2016-2021) & (USD Million) Table 130. Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Type (2021-2026) & (USD Million) Table 131. Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Application (2016-2021) & (USD Million) Table 132. Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Application (2021-2026) & (USD Million) Table 133. Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Country (2016-2021) & (USD Million) Table 134. Middle East & Africa COVID-19 Inactivated Vaccine Revenue by Country (2021-2026) & (USD Million) List of Figures Figure 1. COVID-19 Inactivated Vaccine Picture Figure 2. Global COVID-19 Inactivated Vaccine Revenue Market Share by Type in 2020 Figure 3. In Clinical Trials Figure 4. Out-of-Clinical Trials Figure 5. COVID-19 Inactivated Vaccine Revenue Market Share by Application in 2020 Figure 6. Hospital Picture Figure 7. Clinic Picture Figure 8. Other Picture Figure 9. Global COVID-19 Inactivated Vaccine Revenue, (USD Million): 2020 VS 2021 VS 2026 Figure 10. Global COVID-19 Inactivated Vaccine Revenue and Forecast (2016-2026) & (USD Million) Figure 11. Global COVID-19 Inactivated Vaccine Revenue Market Share by Region (2016-2026) Figure 12. Global COVID-19 Inactivated Vaccine Revenue Market Share by Region in 2020 Figure 13. North America COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2016-2026) Figure 14. Europe COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2016-2026) Figure 15. Asia-Pacific COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2016-2026) Figure 16. South America COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2016-2026) Figure 17. Middle East and Africa COVID-19 Inactivated Vaccine Revenue (USD Million) and Growth Rate (2016-2026) Figure 18. COVID-19 Inactivated Vaccine Market Drivers Figure 19. COVID-19 Inactivated Vaccine Market Restraints Figure 20. COVID-19 Inactivated Vaccine Market Trends Figure 21. Inovio Pharmaceuticals Recent Developments and Future Plans Figure 22. Takis Biotech (Evvivax) Recent Developments and Future Plans Figure 23. Zydus Cadila Recent Developments and Future Plans Figure 24. Codagenix, Inc. Recent Developments and Future Plans Figure 25. GeoVax, Inc. Recent Developments and Future Plans Figure 26. Bravovax Recent Developments and Future Plans Figure 27. Janssen Pharmaceutical Companies Recent Developments and Future Plans Figure 28. Altimmune Recent Developments and Future Plans Figure 29. Vaxart Recent Developments and Future Plans Figure 30. CanSino Biologics Recent Developments and Future Plans Figure 31. ExpreS2ion Biotechnologies ApS Recent Developments and Future Plans Figure 32. Clover Biopharmaceuticals Recent Developments and Future Plans Figure 33. GSK Recent Developments and Future Plans Figure 34. Vaxil Bio Ltd. Recent Developments and Future Plans Figure 35. Generex Recent Developments and Future Plans Figure 36. Novavax, Inc. Recent Developments and Future Plans Figure 37. Sanofi Pasteur Recent Developments and Future Plans Figure 38. Baylor Recent Developments and Future Plans Figure 39. iBio, Inc. Recent Developments and Future Plans Figure 40. Moderna, Inc. Recent Developments and Future Plans Figure 41. Curevac Recent Developments and Future Plans Figure 42. ImmunoPrecise Recent Developments and Future Plans Figure 43. Global COVID-19 Inactivated Vaccine Revenue Share by Players in 2020 Figure 44. COVID-19 Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) Figure 45. Global Top 3 Players COVID-19 Inactivated Vaccine Revenue Market Share in 2020 Figure 46. Global Top 10 Players COVID-19 Inactivated Vaccine Revenue Market Share in 2020 Figure 47. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021) Figure 48. Global COVID-19 Inactivated Vaccine Revenue Share by Type in 2020 Figure 49. Global COVID-19 Inactivated Vaccine Market Share Forecast by Type (2021-2026) Figure 50. Global COVID-19 Inactivated Vaccine Revenue Share by Application in 2020 Figure 51. Global COVID-19 Inactivated Vaccine Market Share Forecast by Application (2021-2026) Figure 52. North America COVID-19 Inactivated Vaccine Sales Market Share by Type (2016-2026) Figure 53. North America COVID-19 Inactivated Vaccine Sales Market Share by Application (2016-2026) Figure 54. North America COVID-19 Inactivated Vaccine Revenue Market Share by Country (2016-2026) Figure 55. United States COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 56. Canada COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 57. Mexico COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 58. Europe COVID-19 Inactivated Vaccine Sales Market Share by Type (2016-2026) Figure 59. Europe COVID-19 Inactivated Vaccine Sales Market Share by Application (2016-2026) Figure 60. Europe COVID-19 Inactivated Vaccine Revenue Market Share by Country (2016-2026) Figure 61. Germany COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 62. France COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 63. United Kingdom COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 64. Russia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 65. Italy COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 66. Asia-Pacific COVID-19 Inactivated Vaccine Sales Market Share by Type (2016-2026) Figure 67. Asia-Pacific COVID-19 Inactivated Vaccine Sales Market Share by Application (2016-2026) Figure 68. Asia-Pacific COVID-19 Inactivated Vaccine Revenue Market Share by Region (2016-2026) Figure 69. China COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 70. Japan COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 71. South Korea COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 72. India COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 73. Southeast Asia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 74. Australia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 75. South America COVID-19 Inactivated Vaccine Sales Market Share by Type (2016-2026) Figure 76. South America COVID-19 Inactivated Vaccine Sales Market Share by Application (2016-2026) Figure 77. South America COVID-19 Inactivated Vaccine Revenue Market Share by Country (2016-2026) Figure 78. Brazil COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 79. Argentina COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 80. Middle East and Africa COVID-19 Inactivated Vaccine Sales Market Share by Type (2016-2026) Figure 81. Middle East and Africa COVID-19 Inactivated Vaccine Sales Market Share by Application (2016-2026) Figure 82. Middle East and Africa COVID-19 Inactivated Vaccine Revenue Market Share by Country (2016-2026) Figure 83. Turkey COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 84. Saudi Arabia COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 85. UAE COVID-19 Inactivated Vaccine Revenue and Growth Rate (2016-2026) & (USD Million) Figure 86. Methodology Figure 87. Research Process and Data Source

Qualitative Analysis covers:

  • Industry Status and Trends
  • Manufacturer/Company profiles, manufacturing base distribution, sales areas, product introduction, main business, market position and their competitors.
  • Product Development, Technology, Price, Cost, Manufacturing Process and Trends
  • Market segment by regions, types, applications and forecast
  • Market opportunities, potential, government policies and influence factors.
     

Quantitative Analysis covers:

  • Market size (value, sales/output, historical data and forecasts)
  • Sales/output/capacity, revenue, price, gross margin, market share, for top players. Through interviewing each manufacturers,  distributors, traders, dealers and buyers etc.
  • Cost structure, proportion, price trend, gross margin and trend, status and trend, for 10 years
  • Market size by types, regions, applications for 10 years
  • Market forecast based on the potential demand from downstream clients/buyers, government, influence factors and the total economic indication, maybe occur in following years.
     

Data Sources:

Methodology

 

Publisher: GlobalInfoResearch
Chat with us